ArticleBMC medical genomics2026
Diagnostic value of karyotyping, CMA/CNV-seq, and WES in fetuses with thickened nuchal translucency: perinatal and two-year follow-up outcomes.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to analyze the perinatal and pediatric outcomes of fetuses with thickened nuchal translucency (NT ≥ 2.5 mm) to enhance prenatal diagnostic strategies. STUDY
designA total of 720 pregnant women with NT ≥ 2.5 mm in the first trimester underwent interventional prenatal diagnosis. These participants were followed up during the perinatal and pediatric periods (2 years after birth).
resultsThe detection rate of fetal chromosomal karyotype abnormalities was 32.86%, with trisomy 21 being the most common abnormality. Chromosomal microarray analysis (CMA) and copy number variation sequencing (CNV-seq) increased the detection rate by 10.72%. The most prevalent pathogenic copy number variations (pCNVs) and likely pathogenic copy number variations (lpCNVs) were associated with 22q11.21 microdeletion/duplication syndrome and 15q11.2 microdeletion syndrome, respectively. Excluding pathogenic karyotype abnormalities and pCNV/lpCNVs, the rate of pathological deformities was 19.6%. Whole-exome sequencing (WES) was performed in 11 cases, yielding a detection rate of 72.7% (8/11). There were 339 pregnancy terminations and 381 live births, of which 337 had normal karyotypes, CNVs, and ultrasound results, resulting in a live-birth detection rate of 96.8%. In addition, two cases of psychomotor retardation were identified.
conclusionTraditional karyotyping, CMA/CNV-seq testing, and detailed ultrasound examinations are vital diagnostic tools that support genetic counseling for fetuses with thickened NT in the first trimester. Therefore, novel and efficient WES testing is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.